Terms: = Colorectal cancer AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb AND Treatment
18 results:
1. A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle.
Li Y; Zhao D; Zhang W; Yang M; Wu Z; Shi W; Lan S; Guo Z; Yu H; Wu D
J Transl Med; 2023 Jun; 21(1):422. PubMed ID: 37386467
[TBL] [Abstract] [Full Text] [Related]
2. Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials.
Donnelly M; Ryan OK; Ryan ÉJ; Creavin B; O'Reilly M; McDermott R; Kennelly R; Hanly A; Martin ST; Winter DC
Br J Surg; 2023 Sep; 110(10):1316-1330. PubMed ID: 37330950
[TBL] [Abstract] [Full Text] [Related]
3. Up-regulation of ABCG2 by mybL2 deletion drives Chlorin e6-mediated photodynamic therapy resistance in colorectal cancer.
Hui YJ; Chen H; Peng XC; Li LG; Di MJ; Liu H; Hu XH; Yang Y; Zhao KL; Li TF; Yu TT; Wang WX
Photodiagnosis Photodyn Ther; 2023 Jun; 42():103558. PubMed ID: 37030434
[TBL] [Abstract] [Full Text] [Related]
4. treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.
Zheng S; Li H; Lin Y; Xie Y; Yin Z; Ge W; Yu T
Anticancer Drugs; 2022 Jan; 33(1):e548-e554. PubMed ID: 34321419
[TBL] [Abstract] [Full Text] [Related]
5. myb mediates downregulation of the colorectal cancer metastasis suppressor heterogeneous nuclear ribonucleoprotein L-like during epithelial-mesenchymal transition.
Sakuma K; Sasaki E; Hosoda W; Komori K; Shimizu Y; Yatabe Y; Aoki M
Cancer Sci; 2021 Sep; 112(9):3846-3855. PubMed ID: 34286904
[TBL] [Abstract] [Full Text] [Related]
6. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.
Kadioglu O; Saeed M; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
Arch Toxicol; 2021 Mar; 95(3):959-974. PubMed ID: 33515271
[TBL] [Abstract] [Full Text] [Related]
7. Use of Gene Expression Analysis for Discrimination of Primary and Secondary Adenocarcinoma of the Liver.
Hass HG; Vogel U; Scheurlen M; Jobst J
Oncology; 2018; 95(4):211-219. PubMed ID: 29920486
[TBL] [Abstract] [Full Text] [Related]
8. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7.
Zeng K; Chen X; Xu M; Liu X; Hu X; Xu T; Sun H; Pan Y; He B; Wang S
Cell Death Dis; 2018 Apr; 9(4):417. PubMed ID: 29549306
[TBL] [Abstract] [Full Text] [Related]
9. Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of b‑myb and miRNA34a expression.
Lee YJ; Kang YR; Lee SY; Jin Y; Han DC; Kwon BM
Int J Oncol; 2017 Oct; 51(4):1331-1342. PubMed ID: 28902363
[TBL] [Abstract] [Full Text] [Related]
10. miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent colorectal Adenocarcinoma.
Kontos CK; Tsiakanikas P; Avgeris M; Papadopoulos IN; Scorilas A
Mol Diagn Ther; 2017 Aug; 21(4):453-464. PubMed ID: 28405803
[TBL] [Abstract] [Full Text] [Related]
11. Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2.
Wilkins HR; Doucet K; Duke V; Morra A; Johnson N
Tumour Biol; 2010 Jan; 31(1):16-22. PubMed ID: 20237898
[TBL] [Abstract] [Full Text] [Related]
12. Expression of stress response protein glucose regulated protein-78 mediated by c-myb.
Ramsay RG; Ciznadija D; Mantamadiotis T; Anderson R; Pearson R
Int J Biochem Cell Biol; 2005 Jun; 37(6):1254-68. PubMed ID: 15778089
[TBL] [Abstract] [Full Text] [Related]
13. Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells.
Abaza MS; Al-Attiyah RJ; Al-Saffar AM; Al-Sawan SM; Moussa NM
Tumour Biol; 2003; 24(5):241-57. PubMed ID: 15001837
[TBL] [Abstract] [Full Text] [Related]
14. Transcriptional regulation of cyclo-oxygenase expression: three pillars of control.
Ramsay RG; Ciznadija D; Vanevski M; Mantamadiotis T
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):59-67. PubMed ID: 14552705
[TBL] [Abstract] [Full Text] [Related]
15. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-myb.
Ramsay RG; Friend A; Vizantios Y; Freeman R; Sicurella C; Hammett F; Armes J; Venter D
Cancer Res; 2000 Apr; 60(7):1805-9. PubMed ID: 10766162
[TBL] [Abstract] [Full Text] [Related]
16. myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract] [Full Text] [Related]
17. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.
Del Bufalo D; Cucco C; Leonetti C; Citro G; D'Agnano I; Benassi M; Geiser T; Zon G; Calabretta B; Zupi G
Br J Cancer; 1996 Aug; 74(3):387-93. PubMed ID: 8695353
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.
Melani C; Rivoltini L; Parmiani G; Calabretta B; Colombo MP
Cancer Res; 1991 Jun; 51(11):2897-901. PubMed ID: 2032228
[TBL] [Abstract] [Full Text] [Related]
